We are extremely excited that the CRASH-3 trial is now in the final phase – with just 7 months left until we reach our 13,000 patient sample size.
To date 171 hospitals in 28 countries have enrolled patients – an incredible global collaboration of doctors, nurses, intensivists, pharmacists and everyone else involved.
We must continue to strive for early randomisation and treatment and to recruit all eligible patients.
Thanks to the global team for making the CRASH-3 trial a success.
The countdown to 13,000 patients is on!!!